Vol 66, No 2 (2015)
Original paper
Published online: 2015-05-01

open access

Page views 2376
Article views/downloads 2987
Get Citation

Connect on Social Media

Connect on Social Media

Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland — two years of data from Lanro-Study

Ewa Orlewska, Beata Kos-Kudla, Jerzy Sowinski, Krzysztof Sworczak, Wojciech Zgliczynski, Lanro-Study Group
DOI: 10.5603/EP.2015.0022
Pubmed: 25931045
Endokrynol Pol 2015;66(2):142-148.

Abstract

Introduction: To evaluate, over 24 months of prospective follow-up, the dosage and costs of lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre, non-interventional, observational prospective study on resource utilisation in Polish acromegalic patients treated with ATG120 at 4-week or extended (> 4 weeks) dosing interval. The study population consisted of adult acromegalic patients treated for at least 3 injections of ATG120. The endpoints were: percentage of patients treated with ATG120 at an extended dosing interval (> 4 weeks), mean time between injections, and the cost of ATG120 during a 24-month prospective observation. Costs were calculated in PLN from the public health-care payer and patient perspective for the year 2014.
Results: 143 patients were enrolled in, and 132 completed (70% women, 81% macroadenoma, 75% previous surgery) the analysis. During two years, changes in the treatment pattern were reported in 41 patients: 17% of them had increased injection interval and 10% switched to octreotide LAR and then returned to ATG120. Sixty-three patients (48%) received ATG120 at an extended dosing interval. ATG120 was predominantly administered in an out-patient setting (84%) by a health care professional (97%).
Conclusions: The results demonstrated that extended dosing interval of ATG120 is used in a substantial proportion of patients in routine clinical practice in Poland. Such findings support the potential for ATG120 in reducing treatment burden in the real-world clinical environment. (Endokrynol Pol 2015; 66 (2): 142–148)